BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Clercq E. Highlights in the development of new antiviral agents. Mini Rev Med Chem. 2002;2:163-175. [PMID: 12370077 DOI: 10.2174/1389557024605474] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Silvestri R, Artico M, De Martino G, La Regina G, Loddo R, La Colla M, Mura M, La Colla P. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. J Med Chem 2004;47:3892-6. [PMID: 15239667 DOI: 10.1021/jm031147e] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
2 Cheng H, Zhang HZ, Shen WA, Liu YF, Ma FC. Expression of RNase H of human hepatitis B virus polymerase in Escherichia coli. World J Gastroenterol 2003;9:513-5. [PMID: 12632508 DOI: 10.3748/wjg.v9.i3.513] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Steindl TM, Schuster D, Laggner C, Langer T. Parallel screening: a novel concept in pharmacophore modeling and virtual screening. J Chem Inf Model 2006;46:2146-57. [PMID: 16995745 DOI: 10.1021/ci6002043] [Cited by in Crossref: 81] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
4 Winum J, Scozzafava A, Montero J, Supuran CT. Sulfamates and their therapeutic potential. Med Res Rev 2005;25:186-228. [DOI: 10.1002/med.20021] [Cited by in Crossref: 152] [Cited by in F6Publishing: 113] [Article Influence: 8.9] [Reference Citation Analysis]
5 Silvestri R, Artico M, La Regina G, De Martino G, La Colla M, Loddo R, La Colla P. Anti-HIV-1 activity of pyrryl aryl sulfone (PAS) derivatives: synthesis and SAR studies of novel esters and amides at the position 2 of the pyrrole nucleus. Farmaco 2004;59:201-10. [PMID: 14987983 DOI: 10.1016/j.farmac.2003.11.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
6 La Regina G, Coluccia A, Silvestri R. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors. Antivir Chem Chemother 2010;20:213-37. [PMID: 20710063 DOI: 10.3851/IMP1607] [Cited by in Crossref: 45] [Cited by in F6Publishing: 9] [Article Influence: 4.1] [Reference Citation Analysis]
7 Arab Chamjangali M, Beglari M, Bagherian G. Prediction of cytotoxicity data (CC(50)) of anti-HIV 5-phenyl-1-phenylamino-1H-imidazole derivatives by artificial neural network trained with Levenberg-Marquardt algorithm. J Mol Graph Model 2007;26:360-7. [PMID: 17350867 DOI: 10.1016/j.jmgm.2007.01.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
8 Panattoni A, D'Anna F, Triolo E. Antiviral activity of tiazofurin and mycophenolic acid against Grapevine leafroll-associated virus 3 in Vitis vinifera explants. Antiviral Res 2007;73:206-11. [PMID: 17125850 DOI: 10.1016/j.antiviral.2006.10.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
9 Kawasuji T, Johns BA, Yoshida H, Taishi T, Taoda Y, Murai H, Kiyama R, Fuji M, Yoshinaga T, Seki T, Kobayashi M, Sato A, Fujiwara T. Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore. J Med Chem 2012;55:8735-44. [PMID: 22963135 DOI: 10.1021/jm3010459] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
10 Bu H, Pool WF, Wu EY, Raber SR, Amantea MA, Shetty BV. METABOLISM AND EXCRETION OF CAPRAVIRINE, A NEW NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR, ALONE AND IN COMBINATION WITH RITONAVIR IN HEALTHY VOLUNTEERS. Drug Metab Dispos 2004;32:689-98. [DOI: 10.1124/dmd.32.7.689] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
11 Daelemans D, Pannecouque C, Pavlakis GN, Tabarrini O, De Clercq E. A novel and efficient approach to discriminate between pre- and post-transcription HIV inhibitors. Mol Pharmacol 2005;67:1574-80. [PMID: 15728798 DOI: 10.1124/mol.104.010249] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
12 Piscitelli F, Coluccia A, Brancale A, La Regina G, Sansone A, Giordano C, Balzarini J, Maga G, Zanoli S, Samuele A, Cirilli R, La Torre F, Lavecchia A, Novellino E, Silvestri R. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. J Med Chem 2009;52:1922-34. [PMID: 19281225 DOI: 10.1021/jm801470b] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
13 Strouse JJ, Jeselnik M, Tapaha F, Jonsson CB, Parker WB, Arterburn JB. Copper catalyzed arylation with boronic acids for the synthesis of N1-aryl purine nucleosides. Tetrahedron Letters 2005;46:5699-702. [DOI: 10.1016/j.tetlet.2005.06.083] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
14 Lagoja IM, De Clercq E. Anti-influenza virus agents: synthesis and mode of action. Med Res Rev 2008;28:1-38. [PMID: 17160999 DOI: 10.1002/med.20096] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
15 Barić I. Inherited disorders in the conversion of methionine to homocysteine. J Inherit Metab Dis 2009;32:459-71. [PMID: 19585268 DOI: 10.1007/s10545-009-1146-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
16 Hübel K, Liles WC, Broxmeyer HE, Rodger E, Wood B, Cooper S, Hangoc G, Macfarland R, Bridger GJ, Henson GW, Calandra G, Dale DC. Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist. Supportive Cancer Therapy 2004;1:165-72. [DOI: 10.3816/sct.2004.n.008] [Cited by in Crossref: 78] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
17 Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Progress in Biophysics and Molecular Biology 2005;88:209-31. [DOI: 10.1016/j.pbiomolbio.2004.07.001] [Cited by in Crossref: 183] [Cited by in F6Publishing: 152] [Article Influence: 11.4] [Reference Citation Analysis]
18 Majewska A, Lasek W, Janyst M, Młynarczyk G. Inhibition of adenovirus multiplication by inosine pranobex and interferon α in vitro. Cent Eur J Immunol 2015;40:395-9. [PMID: 26862302 DOI: 10.5114/ceji.2015.56960] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
19 Kiritsis C, Manta S, Parmenopoulou V, Dimopoulou A, Kollatos N, Papasotiriou I, Balzarini J, Komiotis D. Stereocontrolled synthesis of 4′-C-cyano and 4′-C-cyano-4′-deoxy pyrimidine pyranonucleosides as potential chemotherapeutic agents. Carbohydrate Research 2012;364:8-14. [DOI: 10.1016/j.carres.2012.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 Lü JM, Yan S, Jamaluddin S, Weakley SM, Liang Z, Siwak EB, Yao Q, Chen C. Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro. Med Sci Monit 2012;18:BR293-298. [PMID: 22847190 DOI: 10.12659/msm.883261] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
21 Abed Y, Boivin G. Treatment of respiratory virus infections. Antiviral Res 2006;70:1-16. [PMID: 16513187 DOI: 10.1016/j.antiviral.2006.01.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
22 Yu M, Ocando JE, Trombetta L, Chatterjee P. Molecular interaction studies of amorphous solid dispersions of the antimelanoma agent betulinic acid. AAPS PharmSciTech 2015;16:384-97. [PMID: 25331193 DOI: 10.1208/s12249-014-0220-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
23 Sastry KS, Zitter TA. Management of Virus and Viroid Diseases of Crops in the Tropics. Plant Virus and Viroid Diseases in the Tropics. Dordrecht: Springer Netherlands; 2014. pp. 149-480. [DOI: 10.1007/978-94-007-7820-7_2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
24 Forsman JJ, Wärnå J, Murzin DY, Leino R. Reaction Kinetics and Mechanism of Sulfuric Acid-Catalyzed Acetolysis of Acylated Methyl L-Ribofuranosides. Eur J Org Chem 2009;2009:5666-76. [DOI: 10.1002/ejoc.200900889] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 San Juan AA. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations. Bioorganic & Medicinal Chemistry Letters 2008;18:1181-94. [DOI: 10.1016/j.bmcl.2007.11.134] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
26 Hoof SV, Ruttens B, Hubrecht I, Smans G, Blom P, Sas B, Van hemel J, Vandenkerckhove J, Van der Eycken J. Synthesis and screening of bicyclic carbohydrate-based compounds: A novel type of antivirals. Bioorganic & Medicinal Chemistry Letters 2006;16:1495-8. [DOI: 10.1016/j.bmcl.2005.12.048] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
27 Butler MS. Natural products to drugs: natural product derived compounds in clinical trials. Nat Prod Rep 2005;22:162-95. [PMID: 15806196 DOI: 10.1039/b402985m] [Cited by in Crossref: 376] [Cited by in F6Publishing: 255] [Article Influence: 23.5] [Reference Citation Analysis]
28 Ragno R, Coluccia A, La Regina G, Silvestri R. Indolyl aryl sulphones as HIV-1 reverse transcriptase inhibitors: docking and 3D QSAR studies. Expert Opinion on Drug Discovery 2007;2:87-114. [DOI: 10.1517/17460441.2.1.87] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
29 Turpin JA. The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets. Expert Review of Anti-infective Therapy 2014;1:97-128. [DOI: 10.1586/14787210.1.1.97] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
30 Médici R, Lewkowicz E, Iribarren A. Microbial synthesis of 2,6-diaminopurine nucleosides. Journal of Molecular Catalysis B: Enzymatic 2006;39:40-4. [DOI: 10.1016/j.molcatb.2006.01.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
31 Kumar D, Kumar V, Marwaha R, Singh G. Oxadiazole-An Important Bioactive Scaffold for Drug Discovery and Development Process Against HIV and Cancer- A Review. CBC 2019;15:271-9. [DOI: 10.2174/1573407213666171017160359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Dimopoulou A, Manta S, Kiritsis C, Gkaragkouni D, Papasotiriou I, Balzarini J, Komiotis D. Rapid microwave-enhanced synthesis of C5-alkynyl pyranonucleosides as novel cytotoxic antitumor agents. Bioorganic & Medicinal Chemistry Letters 2013;23:1330-3. [DOI: 10.1016/j.bmcl.2012.12.092] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
33 Cancio R, Silvestri R, Ragno R, Artico M, De Martino G, La Regina G, Crespan E, Zanoli S, Hübscher U, Spadari S, Maga G. High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme. Antimicrob Agents Chemother 2005;49:4546-54. [PMID: 16251294 DOI: 10.1128/AAC.49.11.4546-4554.2005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
34 Ammendolia MG, Pietrantoni A, Tinari A, Valenti P, Superti F. Bovine lactoferrin inhibits echovirus endocytic pathway by interacting with viral structural polypeptides. Antiviral Res 2007;73:151-60. [PMID: 17023058 DOI: 10.1016/j.antiviral.2006.09.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
35 Winum J, Scozzafava A, Montero J, Supuran CT. Therapeutic applications of sulfamates. Expert Opinion on Therapeutic Patents 2005;14:1273-308. [DOI: 10.1517/13543776.14.9.1273] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
36 Baric I, Fumic K, Glenn B, Cuk M, Schulze A, Finkelstein JD, James SJ, Mejaski-Bosnjak V, Pazanin L, Pogribny IP, Rados M, Sarnavka V, Scukanec-Spoljar M, Allen RH, Stabler S, Uzelac L, Vugrek O, Wagner C, Zeisel S, Mudd SH. S-adenosylhomocysteine hydrolase deficiency in a human: a genetic disorder of methionine metabolism. Proc Natl Acad Sci U S A 2004;101:4234-9. [PMID: 15024124 DOI: 10.1073/pnas.0400658101] [Cited by in Crossref: 152] [Cited by in F6Publishing: 129] [Article Influence: 8.9] [Reference Citation Analysis]
37 Kagan R, Winters M, Merigan T, Heseltine P. HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. AIDS Res Hum Retroviruses 2004;20:1-9. [PMID: 15000693 DOI: 10.1089/088922204322749440] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
38 Gayakhe V, Bhilare S, Yashmeen A, Fairlamb IJ, Kapdi AR. Transition-Metal Catalyzed Modification of Nucleosides. Palladium-Catalyzed Modification of Nucleosides, Nucleotides and Oligonucleotides. Elsevier; 2018. pp. 167-95. [DOI: 10.1016/b978-0-12-811292-2.00006-4] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
39 Sakamoto T, Cullen MD, Hartman TL, Watson KM, Buckheit RW, Pannecouque C, De Clercq E, Cushman M. Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems. J Med Chem 2007;50:3314-21. [PMID: 17579385 DOI: 10.1021/jm070236e] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
40 La Regina G, Coluccia A, Piscitelli F, Bergamini A, Sinistro A, Cavazza A, Maga G, Samuele A, Zanoli S, Novellino E, Artico M, Silvestri R. Indolyl Aryl Sulfones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors:  Role of Two Halogen Atoms at the Indole Ring in Developing New Analogues with Improved Antiviral Activity. J Med Chem 2007;50:5034-8. [DOI: 10.1021/jm070488f] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
41 Witvrouw M, Fikkert V, Hantson A, Pannecouque C, O'keefe BR, McMahon J, Stamatatos L, de Clercq E, Bolmstedt A. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J Virol 2005;79:7777-84. [PMID: 15919930 DOI: 10.1128/JVI.79.12.7777-7784.2005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
42 Sension M. Initial Therapy for Human Immunodeficiency Virus: Broadening the Options. HIV Clinical Trials 2015;5:99-111. [DOI: 10.1310/0h45-8qwu-faud-7e36] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Meyding-lamadé U. S1-Leitlinie: Virale Meningoenzephalitis: Leitlinie der Deutschen Gesellschaft für Neurologie. DGNeurologie 2019;2:92-102. [DOI: 10.1007/s42451-019-0056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Morningstar ML, Roth T, Farnsworth DW, Smith MK, Watson K, Buckheit RW Jr, Das K, Zhang W, Arnold E, Julias JG, Hughes SH, Michejda CJ. Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme. J Med Chem 2007;50:4003-15. [PMID: 17663538 DOI: 10.1021/jm060103d] [Cited by in Crossref: 70] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
45 Walker MP, Appleby TC, Zhong W, Lau JY, Hong Z. Hepatitis C virus therapies: current treatments, targets and future perspectives. Antivir Chem Chemother 2003;14:1-21. [PMID: 12790512 DOI: 10.1177/095632020301400101] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
46 Kawasuji T, Yoshinaga T, Sato A, Yodo M, Fujiwara T, Kiyama R. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores. Bioorg Med Chem 2006;14:8430-45. [PMID: 17010623 DOI: 10.1016/j.bmc.2006.08.044] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
47 Postorino MC, Prosperi M, Focà E, Quiros-Roldan E, Di Filippo E, Maggiolo F, Borghetti A, Ladisa N, Di Pietro M, Gori A, Sighinolfi L, Pan A, Mazzini N, Torti C. Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort. BMC Infect Dis 2017;17:212. [PMID: 28298195 DOI: 10.1186/s12879-017-2322-z] [Reference Citation Analysis]
48 Arnott G, Hunter R, Mbeki L, Mohamed E. New methodology for 2-alkylation of 3-furoic acids: application to the synthesis of tethered UC-781/d4T bifunctional HIV reverse-transcriptase inhibitors. Tetrahedron Letters 2005;46:4023-6. [DOI: 10.1016/j.tetlet.2005.04.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
49 Ribone SR, Quevedo MA, Madrid M, Briñón MC. Rational Approaches for the Design of Effective Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitors. J Chem Inf Model 2011;51:130-8. [DOI: 10.1021/ci1001636] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
50 Bu H, Kang P, Zhao P, Pool WF, Wu EY. A SIMPLE SEQUENTIAL INCUBATION METHOD FOR DECONVOLUTING THE COMPLICATED SEQUENTIAL METABOLISM OF CAPRAVIRINE IN HUMANS. Drug Metab Dispos 2005;33:1438-45. [DOI: 10.1124/dmd.105.005413] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
51 Biron Z, Khare S, Quadt SR, Hayek Y, Naider F, Anglister J. The 2F5 Epitope Is Helical in the HIV-1 Entry Inhibitor T-20. Biochemistry 2005;44:13602-11. [DOI: 10.1021/bi0509245] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
52 Auewarakul P, Wacharapornin P, Srichatrapimuk S, Chutipongtanate S, Puthavathana P. Uncoating of HIV-1 requires cellular activation. Virology 2005;337:93-101. [PMID: 15882886 DOI: 10.1016/j.virol.2005.02.028] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
53 Arab Chamjangali M. Modelling of Cytotoxicity Data (CC 50 ) of Anti-HIV 1-[5-Chlorophenyl) Sulfonyl]-1H-Pyrrole Derivatives Using Calculated Molecular Descriptors and Levenberg-Marquardt Artificial Neural Network. Chemical Biology & Drug Design 2009;73:456-65. [DOI: 10.1111/j.1747-0285.2009.00790.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]